Healthcare
Olympus Corporation(OCPNF)
Live Price
Offline$10.01
+0.00% today
1Y Change
-19.34%
Window
Jun 25, 2025 → Jun 16, 2026
- Market Cap
- $1.73T
- Revenue Growth
- +6.5%
- EPS Growth
- +369.6%
- Dividend Yield
- 1.9%
Coverage: 245 bars · Jun 25, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Olympus Corporation (OCPNF) is a Healthcare stock with a market cap of $1.73T and listed on OTC. The stock last traded around $10.01 and down 19.3% across the available one-year price window (Jun 25, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +6.5%, EPS growth of +369.6%, a dividend yield of 1.9%. What stands out right now is revenue +6.5%, EPS +369.6%, free cash flow +662.7% with operating margin 15.6% and ROIC 9.5%. The dividend is present but secondary, with a yield around 1.9%. Valuation is more restrained than many high-expectation growth names at P/E 20.4 and price/sales 1.8. Stock Foundry combines OCPNF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.5% vs +7.6% peer median
Operating Margin
Below sector median
+15.6% vs +19.4% peer median
P/E
Below sector median
20.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +6.5% and EPS at +369.6%, with operating margin around 15.6%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.9%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
OCPNF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OCPNF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OCPNF Max Drawdown
-42.86%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OCPNF and SPY.
Company Overview
Olympus Corporation
Other OTC
Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through four segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, endoscopy system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Others segment offers biomedical materials and orthopedic equipment. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.
- Leadership
- Frank Drewalowski
- IPO Date
- Jan 13, 2010
- Employees
- 28.8k
- Street Address
- Shinjuku Monolith
- Mailing
- Tokyo, 163-0914
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 3340 2111
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 20.4
- EV/EBITDA
- 8.1
- Price/Sales
- 1.8
- Price/Book
- 2.2
Growth
- Revenue
- +6.5%
- EPS
- +369.6%
- Free Cash Flow
- +662.7%
Profitability
- Gross Margin
- 66.2%
- Operating Margin
- 15.6%
- Net Margin
- 8.6%
- ROE
- 11.3%
- ROIC
- 9.5%
Balance Sheet
- Debt/Equity
- 0.31
- Current Ratio
- 1.63
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.